<DOC>
	<DOCNO>NCT01703962</DOCNO>
	<brief_summary>The recurrent mutation IDH1Arg132His lead cellular accumulation D-2-hydroxyglutarate ( 2-HG ) , thus represent diagnostic marker ( change almost specific glioma ) prognostic ( mutate gliomas longer survival ) interest . The main objective identify patient IDH1 mutate glioma three complementary approach -genetic ( identification IDH1 mutation plasmatic DNA ) , biochemical ( 2-HG dosage urine patient ) radiological ( 2-HG</brief_summary>
	<brief_title>Non Invasive IDentification Gliomas With IDH1 Mutation</brief_title>
	<detailed_description>Our preliminary result indicate extremely high amount D-2HG glioma CSF patient , therefore possibility detect presence spectro-MRI , establish non-invasive diagnosis glioma IDH1 mutation . Our goal identify quantify high-field MRI spectroscopy presence D-2HG identify glioma IDH1 mutation . In parallel , develop technique selective amplification mutate form IDH1 ( COLD PCR ) : combining technique digital PCR , already able detect IDH1 mutation free plasma DNA sensitivity 58 % specificity 100 % . At time show D-2HG level urine patient correlate status tumor IDH1 . The main objective identify use triple approach ( detection mutation plasma DNA detection , detection urinary D-2HG , detection tumor D-2HG spectro-MRI ) patient IDH1arg132His mutation , secondary objective evaluate value marker patient follow-up differentiate recurrence treatment induced damage . 40 patient grade II grade III glioma ( 20 mutate , 20 non mutate ) include follow one year ( five measurement plan ) . The first interest diagnostic : presence IDH1Arg132His mutation allow diagnosis glioma . This information particularly valuable patient amenable biopsy , location tumor consider risk , general condition patient co-morbidities medication . We hope also parameter well monitor patient 's follow-up , new method differentiate tumor recurrence radionecrosis post-radiation leukoencephalopathy .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<criteria>Inclusion Criteria Affiliated Health Insurance regimen ( sécurité sociale ) Patient 18 year write informed consent Glioma grade II III histologically proven Frozen sample available Known status IDH1/IDH2 Presence measurable residual tumor ( &gt; 2 cm diameter FLAIR ) Karnofsky Performance Status ( KPS ) &gt; 60 Contraindication MRI * The rare patient IDH2 mutation non Arg132His IDH1 mutation exclude Inability provide inform consent Patient guardianship deprive liberty court</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Glioma</keyword>
	<keyword>IDH1</keyword>
	<keyword>Spectroscopy</keyword>
	<keyword>Plasma</keyword>
</DOC>